• We studied apraclonidine hydrochloride (aplonidine hydrochloride or ALO 2145), an α-agonist, for its effect on the intraocular pressure (IOP) rise following neodymium-YAG posterior capsulotomy (YPC). In a prospective multicentered double-masked study, 63 eyes were pretreated with one drop of either 1% apraclonidine hydrochloride or placebo one hour before performing YPC and again following the laser treatment. The greatest IOP rise in the placebo-treated eyes occurred in the third hour after YPC, when the mean (±SD) IOP rose from a baseline pressure of 16.4 ± 3.7 to 20.8 ± 6.8 mm Hg. In apraclonidine-treated eyes, the IOP fell from a mean of 15.6 ± 3.8 to 12.8 ± 6.0 mm Hg three hours postoperatively. There were five times as many eyes that had an IOP rise greater than 10 mm Hg in the placebo-treated group compared with those treated with apraclonidine. Apraclonidine proved to be highly effective in preventing the rise in IOP following YPC.
Pollack IP, Brown RH, Crandall AS, Robin AL, Stewart RH, White GL. Prevention of the Rise in Intraocular Pressure Following Neodymium-YAG Posterior Capsulotomy Using Topical 1% Apraclonidine. Arch Ophthalmol. 1988;106(6):754–757. doi:10.1001/archopht.1988.01060130824031
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: